Literature DB >> 26459538

Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations.

P Kambli1, K Ajbani1, C Nikam1, A Khillari1, A Shetty1, Z Udwadia2, S B Georghiou3, T C Rodwell3, A Catanzaro3, C Rodrigues1.   

Abstract

The purpose of the present study was to correlate gyrA mutations found in Mycobacterium tuberculosis isolates using the GenoType(®) MTBDRsl assay with minimum inhibitory concentrations of the fluoroquinolone levofloxacin (LVX). Of 123 archived clinical M. tuberculosis isolates evaluated, 93 isolates had an Ala90Val, Ser91Pro, Asp94Ala, Asn/Tyr, Gly or His mutation and 30 were wild-type. Phenotypically, gyrA mutations Ala90Val, Ser91Pro or Asp94Ala showed a low level of resistance to LVX, while Asp94Asn/Tyr, Asp94Gly or Asp94His mutations had high-level resistance.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26459538      PMCID： PMC4607084          DOI： 10.5588/ijtld.14.0277

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  8 in total

1.  Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China.

Authors:  Xiaomao Yin; Zhaoxian Yu
Journal:  J Infect       Date:  2010-05-07       Impact factor: 6.072

2.  Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India.

Authors:  Kanchan Ajbani; Camilla Rodrigues; Shubhada Shenai; Ajita Mehta
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

3.  Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex.

Authors:  S-Y Grace Lin; Edward Desmond; Donald Bonato; Wendy Gross; Salman Siddiqi
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

4.  Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.

Authors:  Priti Kambli; Kanchan Ajbani; Meeta Sadani; Chaitali Nikam; Anjali Shetty; Zarir Udwadia; Timothy C Rodwell; Antonino Catanzaro; Camilla Rodrigues
Journal:  Tuberculosis (Edinb)       Date:  2014-12-03       Impact factor: 3.131

5.  Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.

Authors:  Elena Yu Nosova; Anastasia A Bukatina; Yulia D Isaeva; Marina V Makarova; Ksenia Yu Galkina; Arkadyi M Moroz
Journal:  J Med Microbiol       Date:  2012-09-27       Impact factor: 2.472

Review 6.  Fluoroquinolones, tuberculosis, and resistance.

Authors:  Amy Sarah Ginsburg; Jacques H Grosset; William R Bishai
Journal:  Lancet Infect Dis       Date:  2003-07       Impact factor: 25.071

7.  Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China.

Authors:  Peng Xu; Xia Li; Ming Zhao; Xiaohong Gui; Kathryn DeRiemer; Sebastien Gagneux; Jian Mei; Qian Gao
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

8.  Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.

Authors:  Jann-Yuan Wang; Li-Na Lee; Hsin-Chih Lai; Shu-Kuan Wang; I-Shiow Jan; Chong-Jen Yu; Po-Ren Hsueh; Pan-Chyr Yang
Journal:  J Antimicrob Chemother       Date:  2007-04-05       Impact factor: 5.790
  8 in total
  6 in total

Review 1.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

Review 2.  GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugs.

Authors:  Grant Theron; Jonny Peter; Marty Richardson; Rob Warren; Keertan Dheda; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2016-09-08

3.  Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Authors:  Devyani Deshpande; Jotam G Pasipanodya; Stellah G Mpagama; Paula Bendet; Shashikant Srivastava; Thearith Koeuth; Pooi S Lee; Sujata M Bhavnani; Paul G Ambrose; Guy Thwaites; Scott K Heysell; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

4.  Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs Among Mycobacterium tuberculosis by a Reverse Dot Blot Hybridization Assay.

Authors:  Guilian Li; Qian Guo; Haican Liu; Li Wan; Yi Jiang; Machao Li; Li-Li Zhao; Xiuqin Zhao; Zhiguang Liu; Kanglin Wan
Journal:  Infect Drug Resist       Date:  2020-11-11       Impact factor: 4.003

5.  What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.

Authors:  Jan Heyckendorf; Sönke Andres; Claudio U Köser; Ioana D Olaru; Thomas Schön; Erik Sturegård; Patrick Beckert; Viola Schleusener; Thomas A Kohl; Doris Hillemann; Danesh Moradigaravand; Julian Parkhill; Sharon J Peacock; Stefan Niemann; Christoph Lange; Matthias Merker
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

6.  Drug-Resistant Tuberculosis, Lebanon, 2016 - 2017.

Authors:  Salam El Achkar; Christine Demanche; Marwan Osman; Rayane Rafei; Mohamad Bachar Ismail; Hiam Yaacoub; Claire Pinçon; Stéphanie Duthoy; Frédérique De Matos; Cyril Gaudin; Alberto Trovato; Daniela M Cirillo; Monzer Hamze; Philip Supply
Journal:  Emerg Infect Dis       Date:  2019-03       Impact factor: 6.883
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.